| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/26/2022 | 48.51% | Barclays | $7 → $6 | Maintains | Overweight |
| 08/11/2022 | 98.02% | Credit Suisse | $8.5 → $8 | Maintains | Outperform |
| 08/11/2022 | 23.76% | Goldman Sachs | $4.5 → $5 | Maintains | Sell |
| 08/11/2022 | 48.51% | Piper Sandler | $5 → $6 | Maintains | Neutral |
| 07/18/2022 | 23.76% | Piper Sandler | $7 → $5 | Maintains | Neutral |
| 07/14/2022 | 11.39% | Goldman Sachs | $6 → $4.5 | Maintains | Sell |
| 07/07/2022 | 48.51% | Keybanc | $7 → $6 | Maintains | Overweight |
| 05/23/2022 | 73.27% | Barclays | $8 → $7 | Maintains | Overweight |
| 05/18/2022 | 147.52% | Credit Suisse | $12 → $10 | Maintains | Outperform |
| 05/18/2022 | 73.27% | Piper Sandler | $10 → $7 | Maintains | Neutral |
| 04/08/2022 | 60.89% | Goldman Sachs | $7 → $6.5 | Maintains | Sell |
| 02/24/2022 | 197.03% | Credit Suisse | $18 → $12 | Maintains | Outperform |
| 02/24/2022 | 147.52% | Piper Sandler | $14 → $10 | Maintains | Neutral |
| 02/22/2022 | 246.53% | Truist Securities | $23 → $14 | Maintains | Buy |
| 01/14/2022 | 147.52% | Keybanc | $18 → $10 | Maintains | Overweight |
| 01/12/2022 | 246.53% | Piper Sandler | $17 → $14 | Maintains | Neutral |
| 12/10/2021 | 122.77% | Goldman Sachs | → $9 | Initiates Coverage On | → Sell |
| 11/17/2021 | 444.55% | Credit Suisse | $34 → $22 | Maintains | Outperform |
| 11/02/2021 | 518.81% | Keybanc | $35 → $25 | Maintains | Overweight |
| 08/23/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 08/23/2021 | 766.34% | Truist Securities | → $35 | Initiates Coverage On | → Buy |
| 08/23/2021 | 716.83% | Barclays | → $33 | Initiates Coverage On | → Overweight |
| 08/23/2021 | 617.82% | JP Morgan | → $29 | Initiates Coverage On | → Neutral |
| 08/23/2021 | 716.83% | Credit Suisse | → $33 | Initiates Coverage On | → Outperform |
| 08/23/2021 | 766.34% | Keybanc | → $35 | Initiates Coverage On | → Overweight |
| 08/23/2021 | 692.08% | Piper Sandler | → $32 | Initiates Coverage On | → Overweight |
Riskified Questions & Answers
The latest price target for Riskified (NYSE: RSKD) was reported by Barclays on September 26, 2022. The analyst firm set a price target for $6.00 expecting RSKD to rise to within 12 months (a possible 48.51% upside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for Riskified (NYSE: RSKD) was provided by Barclays, and Riskified maintained their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Riskified, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Riskified was filed on September 26, 2022 so you should expect the next rating to be made available sometime around September 26, 2023.
While ratings are subjective and will change, the latest Riskified (RSKD) rating was a maintained with a price target of $7.00 to $6.00. The current price Riskified (RSKD) is trading at is $4.04, which is out of the analyst's predicted range.